Evidence for Hypoxia-Induced Shift in ATP Production from Glycolysis to Mitochondrial Respiration in Pulmonary Artery Smooth Muscle Cells in Pulmonary Arterial Hypertension

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Aug 12

PMID 37568430

Authors

Satoshi Akagi

Kazufumi Nakamura

Megumi Kondo

Satoshi Hirohata

Heiichiro Udono

Mikako Nishida

Yukihiro Saito

Masashi Yoshida

Toru Miyoshi

Hiroshi Ito

Affiliations

Soon will be listed here.

Abstract

Background: The metabolic state of pulmonary artery smooth muscle cells (PASMCs) from patients with pulmonary arterial hypertension (PAH) is not well understood. In this study, we examined the balance between glycolysis and mitochondrial respiration in non-PAH-PASMCs and PAH-PASMCs under normoxia and hypoxia.

Methods: We investigated the enzymes involved in glycolysis and mitochondrial respiration, and studied the two major energy-yielding pathways (glycolysis and mitochondrial respiration) by measuring extracellular acidification rate (ECAR) and cellular oxygen consumption rate (OCR) using the Seahorse extracellular flux technology.

Results: Under both normoxia and hypoxia, the mRNA and protein levels of pyruvate dehydrogenase kinase 1 and pyruvate dehydrogenase were increased in PAH-PASMCs compared with non-PAH-PASMCs. The mRNA and protein levels of lactate dehydrogenase, as well as the intracellular lactate concentration, were also increased in PAH-PASMCs compared with non-PAH-PASMCs under normoxia. However, these were not significantly increased in PAH-PASMCs compared with non-PAH-PASMCs under hypoxia. Under normoxia, ATP production was significantly lower in PAH-PASMCs (59 ± 5 pmol/min) than in non-PAH-PASMCs (70 ± 10 pmol/min). On the other hand, ATP production was significantly higher in PAH-PASMCs (31 ± 5 pmol/min) than in non-PAH-PASMCs (14 ± 3 pmol/min) under hypoxia.

Conclusions: There is an underlying change in the metabolic strategy to generate ATP production under the challenge of hypoxia.

Citing Articles

The role of lactate metabolism and lactylation in pulmonary arterial hypertension.

Peng T, Lu J, Zheng X, Zeng C, He Y Respir Res. 2025; 26(1):99.

PMID: 40075458 PMC: 11905457. DOI: 10.1186/s12931-025-03163-3.

Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review).

Chen M, Li H, Li Y, Luo Y, He Y, Shui X Int J Mol Med. 2024; 54(6).

PMID: 39422043 PMC: 11518579. DOI: 10.3892/ijmm.2024.5439.

Expression and regulation of HIF-1a in hypoxic pulmonary hypertension: Focus on pathological mechanism and Pharmacological Treatment.

Wan J, Yi J, Wang F, Zhang C, Dai A Int J Med Sci. 2024; 21(1):45-60.

PMID: 38164358 PMC: 10750340. DOI: 10.7150/ijms.88216.

References

Akagi S, Nakamura K, Matsubara H, Kondo M, Miura D, Matoba T . Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol. 2016; 67(4):290-8. PMC: 4827325. DOI: 10.1097/FJC.0000000000000352. View

Han S, Chandel N . Lessons from Cancer Metabolism for Pulmonary Arterial Hypertension and Fibrosis. Am J Respir Cell Mol Biol. 2021; 65(2):134-145. PMC: 8399574. DOI: 10.1165/rcmb.2020-0550TR. View

Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry M, Bleackley R . Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl). 2011; 89(8):771-83. DOI: 10.1007/s00109-011-0762-2. View

Sommer N, Ghofrani H, Pak O, Bonnet S, Provencher S, Sitbon O . Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2020; 178(1):6-30. DOI: 10.1111/bph.15016. View

Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K . Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation. 2005; 112(12):1806-12. DOI: 10.1161/CIRCULATIONAHA.105.536169. View

Michelakis E, McMurtry M, Wu X, Dyck J, Moudgil R, Hopkins T . Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002; 105(2):244-50. DOI: 10.1161/hc0202.101974. View

Xu W, Janocha A, Erzurum S . Metabolism in Pulmonary Hypertension. Annu Rev Physiol. 2021; 83:551-576. PMC: 8597719. DOI: 10.1146/annurev-physiol-031620-123956. View

McMurtry M, Bonnet S, Wu X, Dyck J, Haromy A, Hashimoto K . Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004; 95(8):830-40. DOI: 10.1161/01.RES.0000145360.16770.9f. View

Akagi S, Matsubara H, Nakamura K, Ito H . Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. J Cardiol. 2018; 72(6):466-472. DOI: 10.1016/j.jjcc.2018.04.014. View

10.

Young J, Williams D, Thompson A . Thin Air, Thick Vessels: Historical and Current Perspectives on Hypoxic Pulmonary Hypertension. Front Med (Lausanne). 2019; 6:93. PMC: 6504829. DOI: 10.3389/fmed.2019.00093. View

11.

Pullamsetti S, Savai R, Seeger W, Goncharova E . Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. Am J Respir Crit Care Med. 2016; 195(4):425-437. PMC: 5803657. DOI: 10.1164/rccm.201606-1226PP. View

12.

Vasan K, Werner M, Chandel N . Mitochondrial Metabolism as a Target for Cancer Therapy. Cell Metab. 2020; 32(3):341-352. PMC: 7483781. DOI: 10.1016/j.cmet.2020.06.019. View

13.

Michelakis E, Gurtu V, Webster L, Barnes G, Watson G, Howard L . Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017; 9(413). DOI: 10.1126/scitranslmed.aao4583. View

14.

Sutendra G, Michelakis E . The metabolic basis of pulmonary arterial hypertension. Cell Metab. 2014; 19(4):558-73. DOI: 10.1016/j.cmet.2014.01.004. View

15.

Smith K, Waypa G, Dudley V, Budinger G, Abdala-Valencia H, Bartom E . Role of Hypoxia-Inducible Factors in Regulating Right Ventricular Function and Remodeling during Chronic Hypoxia-induced Pulmonary Hypertension. Am J Respir Cell Mol Biol. 2020; 63(5):652-664. PMC: 7605159. DOI: 10.1165/rcmb.2020-0023OC. View

16.

Bertero T, Oldham W, Cottrill K, Pisano S, Vanderpool R, Yu Q . Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest. 2016; 126(9):3313-35. PMC: 5004943. DOI: 10.1172/JCI86387. View

17.

Dabral S, Muecke C, Valasarajan C, Schmoranzer M, Wietelmann A, Semenza G . A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension. Nat Commun. 2019; 10(1):2130. PMC: 6513860. DOI: 10.1038/s41467-019-10044-z. View

18.

DeBerardinis R, Chandel N . We need to talk about the Warburg effect. Nat Metab. 2020; 2(2):127-129. DOI: 10.1038/s42255-020-0172-2. View

19.

Cao Y, Zhang X, Wang L, Yang Q, Ma Q, Xu J . PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension. Proc Natl Acad Sci U S A. 2019; 116(27):13394-13403. PMC: 6613097. DOI: 10.1073/pnas.1821401116. View

20.

Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes K, Lopaschuk G . Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010; 2(44):44ra58. DOI: 10.1126/scitranslmed.3001327. View